Second-quarter revenue rose 48% to $23.0bn ($20.7bn expected), driven by Mounjaro and Zepbound sales increasing 91% and 46%, respectively. A 60% increase in volume more than offset a 13% fall in prices,
Adjusted operating profit increased 40% to $9.8bn, driven by strong top-line growth.
Full-year revenue guidance has been upgraded to $85-87bn ($85.4bn expected). Performance margin guidance was also upgraded.
So far in 2026 Eli Lilly has allocated $7.1bn to dividends and share buybacks.
The shares were up 4.4% in early trading.
Our view
HL view to follow.
Eli Lilly key facts
All ratios are sourced from LSEG Datastream, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by LSEG. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.